The FDA on November 10, 2015 approved COTELLIC® Tablets for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with Vemurafenib. COTELLIC® is not indicated for treatment of patients with wild-type BRAF melanoma. COTELLIC® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
